Lonza Group AG (0QNO.L)
LSE - LSE Delayed price. Currency in CHF
Add to watchlist
At close: 05:36PM BST
| Previous close | 484.93 |
| Open | 483.50 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 483.50 - 493.10 |
| 52-week range | 308.40 - 600.90 |
| Volume | |
| Avg. volume | 103,234 |
| Market cap | 36.285B |
| Beta (5Y monthly) | 0.63 |
| PE ratio (TTM) | 0.12 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
NeuroSense Announces First Quarter 2024 Business Update
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, today provides a business update.
- PR Newswire
ABL Bio Taps into Synaffix ADC Technology to Accelerate Development of Bispecific ADC Products
Synaffix B.V., a Lonza company (SIX: LONN) focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announces a licensing agreement to develop bispecific ADCs with ABL Bio, Inc. (KOSDAQ: 298380), a clinical-stage biotech developing bispecific antibody technology for immuno-oncology and neurodegenerative diseases.
© 2024 Yahoo. All rights reserved.